IL17A and Alzheimer disease: Recent clinical trials of the anti-IL-17A antibody secukinumab, a very potent therapeutic agent for treating psoriasis, did not report its satisfactory efficacy against AD (https://clinicaltrials.gov/ct2/show/results/NCT02594098?term=atopic&cond=secukinumab&draw=2&rank=1).